Pettyjohn Wood & White Inc. Lowers Holdings in Merck & Co., Inc. (NYSE:MRK)

Pettyjohn Wood & White Inc. trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 8.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,152 shares of the company’s stock after selling 2,410 shares during the period. Pettyjohn Wood & White Inc.’s holdings in Merck & Co., Inc. were worth $2,201,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Titan Capital Management LLC CA purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA raised its position in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the period. JJJ Advisors Inc. purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $27,000. Cumberland Partners Ltd purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $40,000. Finally, Fusion Family Wealth LLC raised its position in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the period. Institutional investors and hedge funds own 74.95% of the company’s stock.

A number of brokerages have issued reports on MRK. JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, October 10th. Credit Suisse Group restated a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Tuesday, September 3rd. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Argus upped their target price on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus target price of $95.13.

NYSE:MRK traded up $0.71 during midday trading on Friday, hitting $83.59. The stock had a trading volume of 6,348,296 shares, compared to its average volume of 10,105,755. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35. The company has a market capitalization of $212.31 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.80 and a beta of 0.54. The stock has a 50-day moving average of $84.03 and a 200 day moving average of $82.71. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The company had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. During the same quarter in the prior year, the firm earned $1.19 earnings per share. Merck & Co., Inc.’s revenue was up 14.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply